<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40969789</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Intensive glycemic control and kidney disease risk: insights on hierarchical composite endpoint from a randomized clinical trial.</ArticleTitle><Pagination><StartPage>1636392</StartPage><MedlinePgn>1636392</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1636392</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2025.1636392</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Clinical trials of intensive glycemic control in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk have reported inconsistent findings regarding chronic kidney disease (CKD) outcomes, partly due to heterogeneity in event definitions and reliance on conventional time-to-first-event analysis. This study aimed to evaluate the renal effects of intensive glycemic control using a hierarchical composite endpoint (HCE) ranked by clinical severity and analyzed via the Win Odds (WO) method.</AbstractText><AbstractText Label="METHOD" NlmCategory="UNASSIGNED">This post-hoc analysis included patients from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) glycemia trial. We employed the win ratio statistical method to estimate the treatment effects on HCE, defined as a ranked composite of all-cause mortality, kidney failure, sustained estimated glomerular filtration rate (eGFR) declines of 57, 50, and 40% from baseline, persistent eGFR &lt; 15&#x202f;mL/min/1.73&#x202f;m<sup>2</sup>, and eGFR slope. The effects of intensive glycemic control on individual HCE components and various composite kidney endpoints was assessed by Cox regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among the 9,848 participants, sustained 40% eGFR decline was the most frequent renal event in the hierarchical composite. Intensive glucose control was not associated with a significant difference in the HCE compared to standard therapy (WO&#x202f;=&#x202f;1.03, 95% CI: 0.99-1.07). This finding was consistent with results from Cox regression (HR&#x202f;=&#x202f;1.05, 95% CI: 0.97-1.13) and across individual components of the composite endpoint.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In individuals with T2DM at high risk for cardiovascular disease, intensive glycemic control does not demonstrate a significantly detrimental effect on hierarchical composite kidney outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Song, Xu, Zhang, Liu, Li, Chen, Guo and Zhu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Song</LastName><ForeName>Zhaojie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Haibao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Economics and Finance, Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shaanxi International Trust Limited-Liability Company, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiaheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yezhou</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Sujuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Baoji Central Hospital, Baoji, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ni</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Win Odds</Keyword><Keyword MajorTopicYN="N">cardio-renal syndrome</Keyword><Keyword MajorTopicYN="N">cardiovascular risk</Keyword><Keyword MajorTopicYN="N">diabetic kidney disease</Keyword><Keyword MajorTopicYN="N">hierarchical composite endpoint</Keyword><Keyword MajorTopicYN="N">intensive glycemic control</Keyword><Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword></KeywordList><CoiStatement>HX was employed by Shaannxi International Trust Limited-Liability Company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40969789</ArticleId><ArticleId IdType="pmc">PMC12440872</ArticleId><ArticleId IdType="doi">10.3389/fmed.2025.1636392</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crawford AL, Laiteerapong N. Type 2 diabetes. Ann Intern Med. (2024) 177:ITC81-96. doi: 10.7326/AITC202406180, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202406180</ArticleId><ArticleId IdType="pubmed">38857502</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association . Chronic kidney disease and risk management: standards of care in diabetes&#x2014;2024. Diabetes Care. (2024) 47:S219&#x2013;30. doi: 10.2337/dc22-S011</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-S011</ArticleId><ArticleId IdType="pmc">PMC10725805</ArticleId><ArticleId IdType="pubmed">38078574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DL, Lee SE, Kim NH. Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease. Endocrinol Metab. (2023) 38:43&#x2013;55. doi: 10.3803/EnM.2022.1629, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3803/EnM.2022.1629</ArticleId><ArticleId IdType="pmc">PMC10008664</ArticleId><ArticleId IdType="pubmed">36891650</ArticleId></ArticleIdList></Reference><Reference><Citation>Soheilipour F, Abbasi KN, Imankhan M, Eskandari D. Complications and treatment of early-onset type 2 diabetes. Int J Endocrinol Metab. (2023) 21:e135004. doi: 10.5812/ijem-135004</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/ijem-135004</ArticleId><ArticleId IdType="pmc">PMC10676662</ArticleId><ArticleId IdType="pubmed">38028250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachin JM, Nathan DM. Understanding metabolic memory: the prolonged influence of glycemia during the diabetes control and complications trial (DCCT) on future risks of complications during the study of the epidemiology of diabetes interventions and complications (EDIC). Diabetes Care. (2021) 44:2216&#x2013;24. doi: 10.2337/dc20-3097, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-3097</ArticleId><ArticleId IdType="pmc">PMC8929187</ArticleId><ArticleId IdType="pubmed">34548284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical hba(1c) values may explain the type 2 diabetes legacy effect: ukpds 88. Diabetes Care. (2021) 44:2231&#x2013;7. doi: 10.2337/dc20-2439, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-2439</ArticleId><ArticleId IdType="pmc">PMC8740943</ArticleId><ArticleId IdType="pubmed">34244332</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (ukpds 91). Lancet. (2024) 404:145&#x2013;55. doi: 10.1016/S0140-6736(24)00537-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00537-3</ArticleId><ArticleId IdType="pubmed">38772405</ArticleId></ArticleIdList></Reference><Reference><Citation>van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, et al. Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. (2024) 20:433&#x2013;46. doi: 10.1038/s41581-024-00827-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-024-00827-z</ArticleId><ArticleId IdType="pubmed">38570632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Adler S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad Med. (2018) 130:381&#x2013;93. doi: 10.1080/00325481.2018.1457397, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2018.1457397</ArticleId><ArticleId IdType="pubmed">29667921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, et al. Long-term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes. Clin J Am Soc Nephrol. (2018) 13:1693&#x2013;702. doi: 10.2215/CJN.06200518, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.06200518</ArticleId><ArticleId IdType="pmc">PMC6237052</ArticleId><ArticleId IdType="pubmed">30361335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo C, Zoungas S. Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain. Evid Based Med. (2017) 22:219&#x2013;20. doi: 10.1136/ebmed-2017-110806, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ebmed-2017-110806</ArticleId><ArticleId IdType="pubmed">29097446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DH. The beneficial effect of glycemic control against adverse outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Metab J. (2023) 47:484&#x2013;6. doi: 10.4093/dmj.2023.0165, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2023.0165</ArticleId><ArticleId IdType="pmc">PMC10404521</ArticleId><ArticleId IdType="pubmed">37533198</ArticleId></ArticleIdList></Reference><Reference><Citation>Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to control cardiovascular risk in diabetes (accord) trial: design and methods. Am J Cardiol. (2007) 99:21i&#x2013;33i. doi: 10.1016/j.amjcard.2007.03.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2007.03.003</ArticleId><ArticleId IdType="pubmed">17599422</ArticleId></ArticleIdList></Reference><Reference><Citation>Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. (2015) 87:649&#x2013;59. doi: 10.1038/ki.2014.296, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2014.296</ArticleId><ArticleId IdType="pubmed">25229335</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AR, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. (2009) 150:604&#x2013;12. doi: 10.7326/0003-4819-150-9-200905050-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink H, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, et al. Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression. J Am Soc Nephrol. (2023) 34:2025&#x2013;38. doi: 10.1681/ASN.0000000000000243, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.0000000000000243</ArticleId><ArticleId IdType="pmc">PMC10703083</ArticleId><ArticleId IdType="pubmed">37872654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugawara Y, Kanda E, Ohsugi M, Ueki K, Kashihara N, Nangaku M. Egfr slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and egfr &gt; 30 ml/min/1.73 m(2) in the j-dreams cohort. Clin Exp Nephrol. (2024) 28:144&#x2013;52. doi: 10.1007/s10157-023-02408-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-023-02408-z</ArticleId><ArticleId IdType="pmc">PMC10808312</ArticleId><ArticleId IdType="pubmed">37806976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group . KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. (2024) 105:S117&#x2013;314. doi: 10.1016/j.kint.2023.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.10.018</ArticleId><ArticleId IdType="pubmed">38490803</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonesh E, Tighiouart H, Ying J, Heerspink HL, Lewis J, Staplin N, et al. Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med. (2019) 38:4218&#x2013;39. doi: 10.1002/sim.8282</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8282</ArticleId><ArticleId IdType="pubmed">31338848</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J, Verbeeck J, Huang B, Hoaglin DC, Gamalo-Siebers M, Seifu Y, et al. The win odds: statistical inference and regression. J Biopharm Stat. (2023) 33:140&#x2013;50. doi: 10.1080/10543406.2022.2089156, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10543406.2022.2089156</ArticleId><ArticleId IdType="pubmed">35946932</ArticleId></ArticleIdList></Reference><Reference><Citation>Monzo L, Levy B, Duarte K, Baudry G, Combes A, Ouattara A, et al. Use of the win ratio analysis in critical care trials. Am J Respir Crit Care Med. (2024) 209:798&#x2013;804. doi: 10.1164/rccm.202309-1644CP, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202309-1644CP</ArticleId><ArticleId IdType="pubmed">38285595</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner E, Vandemeulebroecke M, Mutze T. Win odds: an adaptation of the win ratio to include ties. Stat Med. (2021) 40:3367&#x2013;84. doi: 10.1002/sim.8967, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8967</ArticleId><ArticleId IdType="pubmed">33860957</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpefors M, Lindholm D, Gasparyan SB. The maraca plot: a novel visualization of hierarchical composite endpoints. Clin Trials. (2023) 20:84&#x2013;8. doi: 10.1177/17407745221134949, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17407745221134949</ArticleId><ArticleId IdType="pubmed">36373800</ArticleId></ArticleIdList></Reference><Reference><Citation>Charu V, Liang JW, Chertow GM, Li J, Montez-Rath ME, Geldsetzer P, et al. Heterogeneous treatment effects of intensive glycemic control on kidney microvascular outcomes and mortality in accord. J Am Soc Nephrol. (2024) 35:216&#x2013;28. doi: 10.1681/ASN.0000000000000272, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.0000000000000272</ArticleId><ArticleId IdType="pmc">PMC10843221</ArticleId><ArticleId IdType="pubmed">38073026</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Ohkuma T, Cooper M, Harrap S, Mancia G, Poulter N, et al. Effects of intensive glycemic control on clinical outcomes among patients with type 2 diabetes with different levels of cardiovascular risk and hemoglobin a(1c) in the advance trial. Diabetes Care. (2020) 43:1293&#x2013;9. doi: 10.2337/dc19-1817, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-1817</ArticleId><ArticleId IdType="pubmed">32193249</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer IH, Sun W, Gao X, Cleary PA, Lachin JM, Molitch ME, et al. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study. Lancet Diabetes Endocrinol. (2014) 2:793&#x2013;800. doi: 10.1016/S2213-8587(14)70155-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(14)70155-X</ArticleId><ArticleId IdType="pmc">PMC4215637</ArticleId><ArticleId IdType="pubmed">25043685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilous R. Microvascular disease: what does the ukpds tell us about diabetic nephropathy? Diabet Med. (2008) 25:25&#x2013;9. doi: 10.1111/j.1464-5491.2008.02496.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.2008.02496.x</ArticleId><ArticleId IdType="pubmed">18717975</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the veterans affairs diabetes trial (vadt). Diabetologia. (2018) 61:295&#x2013;9. doi: 10.1007/s00125-017-4473-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4473-2</ArticleId><ArticleId IdType="pmc">PMC5747983</ArticleId><ArticleId IdType="pubmed">29101421</ArticleId></ArticleIdList></Reference><Reference><Citation>Little DJ, Gasparyan SB, Schloemer P, Jongs N, Brinker M, Karpefors M, et al. Validity and utility of a hierarchical composite end point for clinical trials of kidney disease progression: a review. J Am Soc Nephrol. (2023) 34:1928&#x2013;35. doi: 10.1681/ASN.0000000000000244, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC10703071</ArticleId><ArticleId IdType="pubmed">37807165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornelius E, Lo SC, Huang CN, Wang YH, Yang YS. Association of blood glucose and renal end points in advanced diabetic kidney disease. Diabetes Res Clin Pract. (2020) 161:108011. doi: 10.1016/j.diabres.2020.108011, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108011</ArticleId><ArticleId IdType="pubmed">31991151</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeeck J, De Backer M, Verwerft J, Salvaggio S, Valgimigli M, Vranckx P, et al. Generalized pairwise comparisons to assess treatment effects: jacc review topic of the week. J Am Coll Cardiol. (2023) 82:1360&#x2013;72. doi: 10.1016/j.jacc.2023.06.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.06.047</ArticleId><ArticleId IdType="pubmed">37730293</ArticleId></ArticleIdList></Reference><Reference><Citation>Clodi M, Abrahamian H, Brath H, Schernthaner G, Brix J, Ludvik B, et al. Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (update 2023). Wien Klin Wochenschr. (2023) 135:32&#x2013;44. doi: 10.1007/s00508-023-02186-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-023-02186-4</ArticleId><ArticleId IdType="pmc">PMC10133357</ArticleId><ArticleId IdType="pubmed">37101023</ArticleId></ArticleIdList></Reference><Reference><Citation>An L, Yu Q, Chen L, Tang H, Liu Y, Yuan Q, et al. The association between the decline of egfr and a reduction of hemoglobin a(1c) in type 2 diabetic patients. Front Endocrinol. (2021) 12:723720. doi: 10.3389/fendo.2021.723720, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.723720</ArticleId><ArticleId IdType="pmc">PMC8807519</ArticleId><ArticleId IdType="pubmed">35126306</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>